## AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

- 1-81. (Cancelled).
- 82. (Previously Presented) An isolated antibody or a fragment thereof, wherein the antibody or the fragment thereof recognizes a mammalian GBS toxin receptor and wherein the GBS toxin receptor has at least about 86% identity to SEO ID NO:8.
  - 83-84. (Cancelled).
- 85. (Previously Presented) The isolated antibody or the fragment thereof of Claim 82, wherein the mammalian GBS toxin receptor is expressed on a surface of a cell.
- 86. (Previously Presented) The isolated antibody or the fragment thereof of Claim 82, wherein the isolated antibody is a monoclonal antibody or a polyclonal antibody.
- 87. (Previously Presented) The isolated antibody or the fragment thereof of Claim 82, wherein the isolated antibody or the fragment thereof is generated by a method comprising immunizing an animal with the mammalian GBS toxin receptor or an immunogenic polypeptide fragment thereof having at least six amino acids.
- 88. (Previously Presented) The isolated antibody or the fragment thereof of Claim 82, wherein the isolated antibody is a rabbit antibody or a mouse antibody.
- 89. (Previously Presented) The isolated antibody or the fragment thereof of Claim 82, wherein the isolated antibody recognizes an extracellular domain of the GBS toxin receptor.

U.S. Patent Application No. 10/823,506 Amendment and Response to Non-Final Office Action Page 3

90-96. (Cancelled)

97. (Currently Amended) A composition for detection of a GBS toxin receptor or a polypeptide fragment thereof, comprising a reagent for detection of the GBS toxin receptor, wherein the GBS toxin receptor has at least about 86% identity to SEQ ID NO:8, and wherein the reagent for detection of the GBS toxin receptor is an isolated antibody or a fragment thereof that binds the GBS toxin receptor.

98. (Cancelled)

99. (Currently Amended) The composition of Claim 97 A composition for detection of a GBS toxin receptor or a polypeptide fragment thereof, comprising a reagent for detection of the GBS toxin receptor, wherein the GBS toxin receptor has at least about 86% identity to SEO ID NO:8, and wherein the reagent for detection of the GBS toxin receptor is an isolated antibody or a fragment thereof, wherein the isolated antibody or the fragment thereof recognizes the mammalian GBS toxin receptor.

100-101. (Cancelled).

102. (Currently Amended) The composition of Claim 97 A composition for detection of a GBS toxin receptor or a polypeptide fragment thereof, comprising a reagent for detection of the GBS toxin receptor, wherein the GBS toxin receptor has at least about 86% identity to SEO ID NO:8, and wherein the reagent for detection of the GBS toxin receptor is an isolated antibody or a fragment thereof, wherein the GBS toxin receptor is detected in a cell or a tissue of an animal or a human.

103. (Currently Amended) The isolated antibody or the fragment thereof of Claim 82 An isolated antibody or a fragment thereof, wherein the antibody or the fragment thereof recognizes a mammalian GBS toxin receptor and wherein the GBS toxin receptor has at

U.S. Patent Application No. 10/823,506 Amendment and Response to Non-Final Office Action Page 4

<u>least about 86% identity to SEQ ID NO:8</u>, wherein the isolated antibody or the fragment thereof is an inhibitor of binding of a GBS toxin to the mammalian GBS toxin receptor.

104. (Previously Presented) An isolated composition comprising an antibody or a fragment thereof, wherein the antibody or the fragment thereof recognizes a mammalian GBS toxin receptor, and wherein the GBS toxin receptor has at least about 86% identity to SEQ ID NO:8.

105. (Cancelled).